Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510 SECRETARY OF TO

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

I. Registrant Name					
Hart Health Strategies					
2. Address	rent than previously reported				
3823 Fordham Road, N	.W.				
3. Principal Place of Business (if different controls of the second controls of the second controls of the second control of the sec	erent from line 2)	<u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>	******		
Washington, D.C.	20016				
City: 4. Contact Name	State/zip Telephone	(or Country) E-mail (optional)	5. Senate ID #		
Vicki Hart	(202) 441-3515	vhart@hhstrategies.com	84673113		
7. Client Name Self Pharmaceutical Research Ma	anufactureres of America	6. House ID # 36355008			
TYPE OF REPORT	8. Year <u>2004</u> Midyear a previously filed version of this		r End (July 1-Dec		
_	tion Report 🗋 🖒 Termination	•	11. No Lobbyii		
INCOME OR EXP	ENSES - Complete Eithe	er Line 12 OR Line 13			
12. Lobbying Firms		13. Organizations			
INCOME relating to lobbyin period was:	ng activities for this reporting	EXPENSES relating to lobbying activities for this reperiod were:			
Less than \$10,000 🗆		Less than \$10,000 🗖			
\$10,000 or more 🗀 🖒	\$ 160,000.00 Income (nearest \$20,000)	\$10,000 or more			
Provide a good faith estimate, rounded to the nearest \$20,000 of all lobbying related income from the client (including all		14. REPORTING METHOD. Check accounting method. See instructions for			
	y any other entity for lobbying	☐ Method A. Reporting amounts using LDA defini ☐ Method B. Reporting amounts under section 603			
		Internal Revenue Code Method C. Reporting amounts under section I Internal Revenue Code			
Signature Vick	Dark	Date 01-23-0	05		

LD-2 (REV. 4/03)

PAGE 1 c

Registrant Name Hart Health Strate	egies Client Name	Pharmaceutical Research Manufactureres of An
LOBBYING ACTIVITY. Select as engaged in lobbying on behalf of the cinformation as requested. Attach addition	lient during the reporting	to reflect the general issue areas in which the period. Using a separate page for each con
15. General issue area code HCR	(one per page)	
16. Specific lobbying issues		
Monitoring health legislation and regulati	ion	
17. House(s) of Congress and Federal a	gencies contacted	☐ Check if None
Department of Health and Human South U. S. Senate U.S. House of Representatives	ervices	
18. Name of each individual who acted	as a lobbyist in this issue	area
Name		Covered Official Position (if applicable)
Vicki Hart		
19. Interest of each foreign entity in the	specific issues listed on line	e 16 above Check if None
Signature Vieti	art	Date
Printed Name and Title Vicki Hart, Pres	sident	

Filing #88ab6b5e-058b-4eff-a548-644d63d21560 - Page 3 of 6

Form LD-2 (Rec. 4/03)

Page _____2___

Registrant Name	Hart Health Strategies	_ Client Name	Pharmaceutical Re	esearch Manufactureres	
_	late Page - Complete ONLY	where registra	tion information	has changed.	
20. Client new address		*			
21. Client new principal j	place of business (if different from line	20)			
City 22. New general descript	ion of client's business or activites	State/Zip (or	Country)		
LOBBYIST UPD. 23. Name of each pr	ATE eviously reported individual wh	o is no longer e	spected to act as a	lobbyist for the clien	
ISSUE UPDATE 24. General lobbyin	g issues previously reported tha	t no longer perta	ún		
	RGANIZATIONS ng affiliated organization(s)				
Na	me	Address		Principal Place of B (city and state or co	
26. Name of each p	reviously reported organization	that is no longer	affiliated with the	e registrant or client	
FOREIGN ENT					
Name	Address		al place of business d state or country)	Amount of contribution for lobbying activities	
28. Name of each prev	riously reported foreign entity that it	no longer owns, <u>o</u>	r controls, or is affi	liated with the registran	
Signature	reki tolar		Date	01-23-0	
Printed Name and Titl	e Vicki Hart, President ng #88ab6b5e-058b-4eff-a548-64	4d63d21560 Pag	e 5 of 6		

Form LD-2 (Rev. 4/03)

Page ___3_